BACKGROUND: Cetuximab was demonstrated by clinical trials to improve response rate and survival of patients with metastatic and nonresectable colorectal cancer or carcinoma of the head and neck. Appropriate management of skin toxicity associated with epidermal growth factor receptor inhibitor (EGFR-i) therapy is necessary to allow adequate drug administration and to improve quality of life and outcomes. METHODS: A group of Italian Experts produced recommendations for skin toxicity management using the RAND/UCLA Appropriateness Method. Statements were generated on the basis of a systematic revision of the literature and voted twice by a panel of 40 expert physicians; the second vote was preceded by a meeting of the panelists. RESULTS: Skin toxicity included skin rash, skin dryness, pruritus, paronychia, hair abnormality, and mucositis. Recommendations for prophylaxis and therapeutic interventions for each type of toxicity were proposed. CONCLUSIONS: Interventions that were considered appropriate to improve compliance and outcomes of cancer patients treated with EGFR-i were identified.
BACKGROUND:Cetuximab was demonstrated by clinical trials to improve response rate and survival of patients with metastatic and nonresectable colorectal cancer or carcinoma of the head and neck. Appropriate management of skin toxicity associated with epidermal growth factor receptor inhibitor (EGFR-i) therapy is necessary to allow adequate drug administration and to improve quality of life and outcomes. METHODS: A group of Italian Experts produced recommendations for skin toxicity management using the RAND/UCLA Appropriateness Method. Statements were generated on the basis of a systematic revision of the literature and voted twice by a panel of 40 expert physicians; the second vote was preceded by a meeting of the panelists. RESULTS:Skin toxicity included skin rash, skin dryness, pruritus, paronychia, hair abnormality, and mucositis. Recommendations for prophylaxis and therapeutic interventions for each type of toxicity were proposed. CONCLUSIONS: Interventions that were considered appropriate to improve compliance and outcomes of cancerpatients treated with EGFR-i were identified.
Authors: Anna Liza C Agero; Stephen W Dusza; Cristiane Benvenuto-Andrade; Klaus J Busam; Patricia Myskowski; Allan C Halpern Journal: J Am Acad Dermatol Date: 2006-10 Impact factor: 11.527
Authors: Patrizia Racca; Laura Fanchini; Virginia Caliendo; Giuliana Ritorto; Walter Evangelista; Roberta Volpatto; Enrica Milanesi; Angelica Ciorba; Myriam Paris; Ivan Facilissimo; Giuseppe Macripò; Mario Clerico; Libero Ciuffreda Journal: Clin Colorectal Cancer Date: 2008-01 Impact factor: 4.481
Authors: Eric K Rowinsky; Garry H Schwartz; Jared A Gollob; John A Thompson; Nicholas J Vogelzang; Robert Figlin; Ronald Bukowski; Naomi Haas; Pamela Lockbaum; Yu-Ping Li; Rosalin Arends; Kenneth A Foon; Gisela Schwab; Janice Dutcher Journal: J Clin Oncol Date: 2004-06-21 Impact factor: 44.544
Authors: Weston J Smith; Guankui Wang; Hanmant Gaikwad; Vivian P Vu; Ernest Groman; David W A Bourne; Dmitri Simberg Journal: ACS Nano Date: 2018-12-05 Impact factor: 15.881
Authors: G Aprile; F E Pisa; A Follador; L Foltran; F De Pauli; M Mazzer; S Lutrino; C S Sacco; M Mansutti; G Fasola Journal: Support Care Cancer Date: 2012-06-22 Impact factor: 3.603
Authors: R Berardi; S Rinaldi; D Santini; B Vincenzi; R Giampieri; E Maccaroni; F Marcucci; M Francoletti; A Onofri; A Lucarelli; C Pierantoni; G Tonini; S Cascinu Journal: Support Care Cancer Date: 2014-10-19 Impact factor: 3.603